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Diﬀuse large B-cell non-Hodgkin’s lymphoma (DLBCL) accounting for approximately 30% of new lymphoma diagnoses in
adult patients. Complete remissions (CRs) can be achieved in 45% to 55% of patients and cure in approximately 30–35% with
anthracycline-containing combination chemotherapy. The ageadjusted IPI (aaIPI) has been widely employed, particularly to
“tailor” more intensive therapy such as high-dose therapy (HDT) with autologous hemopoietic stem cell rescue (ASCT). IPI,
however, has failed to reliably predict response to speciﬁc therapies. A subgroup of young patients with poor prognosis exists. To
clarify the role of HDT/ASCT combined with rituximab in the front line therapy a longer follow-up and randomized studies are
needed. The beneﬁt of HDT/ASCT for refractory or relapsed DLBCL is restricted to patients with immunochemosensitive disease.
Currently, clinical and biological research is focused to improve the curability of this setting of patients, mainly young.
1.Introduction
Diﬀuse large B-cell non-Hodgkin’s lymphoma (DLBCL) is
the commonest histological subtype of non-Hodgkin’s lym-
phomas (NHL) accounting for approximately 30% of new
lymphoma diagnoses in adult patients. Because their inci-
denceincreasesinoldage,thisepidemiologicalpatternmight
explain, at least in part, the rapid rise in the number of new
diagnoses observed over the last decades of the 20th century
[1, 2] in which an increase of median age of population has
also been registered.
Complete remissions (CRs) can be achieved in 45% to
55% of patients and cure in approximately 30–35% with
anthracycline-containing combination chemotherapy [3].
The International Prognostic Index (IPI) proposed in the
1993 [4] has been used in the risk stratiﬁcation for patients
with DLBCL for more than a decade. The age-adjusted IPI
(aaIPI) has also been widely employed, particularly to “tai-
lor” more intensive therapy such as high-dose therapy
(HDT) with autologous hemopoietic stem cell rescue
(ASCT). IPI, however, has failed to reliably predict response
to speciﬁc therapies. This, in part, reﬂects the inherent
biological heterogeneity of DLBCL and highlights the need
for more precise, patient-speciﬁc, and biologically based risk
factors. Despite these criticisms, the IPI has proved valuable
for stratiﬁcation of patients in clinical trials and remains the
prognostic system more widely employed in clinical research
and daily practice.
The development of rituximab, a chimeric anti-CD20
monoclonal antibody, has represented a revolutionary ad-
vance in the therapy of hematologic malignancies [5]. The
addition of rituximab to cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) combination has pro-
duced signiﬁcant survival beneﬁts in elderly patients with
untreatedDLBCLcomparedtoCHOPalone[6, 7].Similarly,
the same immunochemotherapy regimen has determined an
improved outcome in young low-risk DLBCL patients [8], as
deﬁned by aaIPI. Thus, ﬁrst line chemotherapy with CHOP
or CHOP-like regimens in combination with rituximab has
become standard care for CD20+ DLBCL patients.
Despite the striking advances in the outcome of DLBCL
patients, a subgroup of young patients with poor prognosis
still exists [9, 10]. Currently, clinical and biological research
is focused to improve the curability of this setting of patients,
mainly young.2 Advances in Hematology
2.HDTwithASCTinFront-Line
Treatment of DLBCL
In the prerituximab era, HDT/ASCT has proven eﬀective as
salvage treatment in patients with chemosensitive relapsed
aggressive NHL [11]. These results suggested the possibility
of improving the outcome of aggressive NHL patients
by including HDT/ASCT in the ﬁrst-line therapy. After
some phase I/II trials supporting the use of this strategy,
HDT/ASCT appeared a promising option for frontline treat-
ment of young patients. However, the results of prospective
randomized trials [12–25] have generated conﬂicting results
and several problems have hampered the comparison of data
(Tables 1 and 2).
Firstly, trials had diﬀerent remission status requirements
for HDT/ASCT [12–25]. In particular, only patients in PR or
CR, after induction therapy (Table 1), were randomized to
receive HDT/ASCT or conventional therapy [12–16]. Sec-
ondly, in other trials, patients were randomized at diagnosis
(Table 2), and HDT/ASCT was employed as part of initial
treatment after shortened [19–21, 25]o rf u l lc o u r s eo f
induction therapies [17, 18, 22–24]. Furthermore, high-dose
sequential (HDS) therapy, a type of induction treatment
based on a diﬀerent “philosophy” from the rationale under-
lying the conventional one, was administered up-front fol-
lowed by HDT/ASCT in three studies [17, 23, 24]. HDS
therapy consists in the administration of several non-cross-
resistant drugs, each given at the maximal tolerated dose
mainly as single agent within the shortest possible interval.
The purpose of this regimen was to prevent the emergence
of drug-resistant tumor clones. Thirdly, a great variety of
therapeutic regimens, both among conventional or high-
dosetreatments,wereemployed.Infact,conventionalCHOP
regimen or CHOP-like combinations were employed in 3
and6trials,respectively,while,intheotherstudies,MACOP-
B or VACOP-B were used [17, 18, 21, 22]. Although the
combination of carmustine, etoposide, cytarabine, and mel-
phalan (BEAM) was the most frequently employed condi-
tioning regimen [15, 16, 18–20, 22, 25], other myeloablative
treatments [12–14, 17, 21, 23, 24] were also used in
several trials. Fourthly, because several of these studies were
designed before the introduction in the clinical practice
of both the IPI prognostic score [4] and the REAL-
WHO histological classiﬁcation [26], trials included varying
proportions of patients with diﬀerent risk categories and
diﬀerent histological subtypes, not all of which were DLBCL.
Despite the poor comparability of these trials, a statistically
signiﬁcant prolongation of PFS or EFS was documented
in four trials [15, 19, 22, 25], but none demonstrated a
signiﬁcant improvement of OS associated with HDT/ASCT
with the exception of a retrospective subgroup analysis [14].
In summary, in the prerituximab era, HDT/ASCT, employed
in front-line therapy, failed to improve the outcome of
aggressive NHL patients.
In the rituximab era, HDT/ASCT for intermediate-high
(I-H) or high-risk (H) aaIPI patients is still a matter of
debate. However, the combination of rituximab with an in-
tensiﬁed treatment strategy has resulted in encouraging
r e s u l t si np h a s eI Is t u d i e s( Table 3). Tarella et al. [27] used
rituximab in combination with modiﬁed HDS chemother-
apy delivered with multiple ASCT followed by a consolida-
tion phase consisting of mitoxantrone (Mito) and melphalan
(L-PAM) with ASCT. In this study, 93 of the 112 patients
enrolled completed the planned therapy. At conclusion of
treatment, the CR rate was 80%. At a median followup of
48 months, the estimated 4-year OS projection was 76%
(CI: 68–85%), and at median followup of 46 months, the
4-year EFS projection was 73% (CI: 64–81%). Vitolo et al.
[28] employed 4 cycles of dose-dense (110mg/mq epiru-
bicin, 1200mg/mq ciclofosfamide, 1.4mg/mq vincristina,
and 40mg/mq prednisone orally days 1 to 5 given every two
weeks) CEOP regimen as induction phase, followed by the
2 cycles of mitoxantrone, cytarabine, and dexamethasone
(MAD) as intensiﬁcation phase. The third phase of study
design consisted of BEAM with ASCT. A total of six
rituximab doses were given, 4 and 2 during induction and
intensiﬁcation phases, respectively. Seventy six of the 94
patients completed treatment and underwent HDT/ASCT.
TheCRratewas82%(CI:73–88%).Withamedianfollowup
for censored patients of 49 months, the 4-year FFS rate was
73% (CI: 63, 5–82, 5%) and the 4-year OS rate was 80%
(CI: 71, 6–88,4%). Dilhuydy et al. [29]r e p o r t e da no v e r a l l
response (OR) rate of 67%. With a median followup of 66
months, the estimated rates (±S D )o f5 - y e a rO Sa n dE F S
r a t e sw e r e7 4 %± 4% and 55% ± 5%, respectively. Fitoussi
etal.[30]treated208patientswithrituximabcombinedwith
cyclophosphamide, vindesine, bleomycin, and prednisolone
(ACVBP) for 4 cycles. This induction therapy was followed
by BEAM with ASCT in 155 responding patients (CR or PR).
A total of 32 patients did not receive HDT/ASCT. Twenty
ﬁve were withdrawn during induction therapy, 6 because of
insuﬃcient response before consolidation and one because
of sudden death. With a median followup of 45 months, the
4-year PFS and OS were estimated at 76% (CI: 69–81%) and
78% (72–83%).
In both the Vitolo and the Fitoussi studies, the results
achieved with the immunochemotherapy strategy were
compared with those obtained in their historical groups of
patients treated with similar sequence of chemotherapy pro-
gram, but not including rituximab. Despite the limitations
intrinsictoretrospectiveanalyses,thesecomparisonsshowed
a clear therapeutic advantage of immunotherapy over
chemotherapyinboththetwomajorendpointsPFSandOS.
Recently two randomized studies conducted by the
SWOG [31]a n dF I L[ 32] have tested the role of HDT/ASCT
inthefrontlinetherapyofunfavorable(I-H/H)patientswith
aggressive NHL. In particular, in the SWOG study, patients
responsive to the CHOP or R-CHOP induction therapy
were randomized to receive one more cycle of R-CHOP
followed by TBI or BCNU-based regimens and ASCT or
three additional cycles of R-CHOP [31]. In this trial, the 2yr
PFS was 69% and 56% in the experimental arm compared
to the standard one (95% CI: 1.18–2.51) P = 0.05, while
no signiﬁcant diﬀerence was documented in the 2-year OS.
The authors conclude that HDT/ASCT improves PFS for
responders, including those induced with R-CHOP, with a
stronger outcome seen for those with H IPI grade. The FIL
study, a multicenter randomized trial with a 2 × 2f a c t o r i a lAdvances in Hematology 3
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Table 3: Studies of HDT/ASCT in unfavorable DLBCL patients.
Author Year n Pathological
phenotype
DLCL
(%)
Immunological
phenotype (%)
aaIPI ≥
2( % ) Therapy
Shorten
induction
yes/no
PFS/EFS
(%)
OS
(%)
Tarella [27] 2007 112 REAL 79 B. 100 100 Modiﬁed R-HDS#1 No 4y:73 4y:76
Vitolo [28] 2009 97 REAL 86 B. 100 100
R-mega CEOP14 ×
4+R - M A D 2 × 2+
BEAM/ASCT
No 4y:73 4y:80
Dilhuydy [29] 2010 42 REAL N.R. B. 100 100
R × 4 + CEEP × 2+
R-MTX/R-MC +
BEAM/ASCT
Yes 5y:55 5y:74
Fitoussi [30] 2011 209 WHO N.R. B. 100 100 R-ACVBP × 4+
BEAM/ASCT Yes 4y:76 4y:78
1Plus radiotherapy at bulky disease.
2Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients.
#See [26].
REAL: revised European-American lymphoma classiﬁcation; WHO: World Health Organization classiﬁcation of NHL; R: rituximab; (mega) CEOP:
cyclophosphamide, epirubicin, vincristine, and prednisone; MAD: mitoxantrone, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine,
and melphalan; CEEP: cyclophosphamide, epirubicin, vindesine, and prednisone; MTX: methotrexate; MC: methotrexate and cytarabine; ACBVP:
doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; N.R.: not reported.
design, compared two rituximab dose-dense treatments (R-
CHOP14versusR-megaCHOP14),followedornotbyBEAM
with ASCT [32]. With a median followup of 23 months, 2-
year PFS was 65% (CI: 59–70%), for the entire group of
enrolled patients and 59% (CI: 51–57%) versus 72% (CI:
64–78%) for no HDT/ASCT versus HDT/ASCT respectively.
So far, the advantage in PFS does not translate in OS
beneﬁt. However, a longer followup will clarify the role
of HDT/ASCT as ﬁrst-line treatment of aaIPI 2-3 DLBCL
patients. These and other randomized studies will deﬁne
whether HDT/ASCT combined with rituximab in the front
line therapy is associated with increased cure rate of unfavor-
able DLBCL patients.
3. HDT with ASCT as Salvage Therapy
In the prerituximab era, the Parma trial established HDT/
ASCT as standard therapy in relapsing aggressive NHL pa-
tients responding to salvage therapy [11].
The parameters aﬀecting the results of HDT/ASCT are
identiﬁed in responsive disease to conventional dose salvage
therapy before myeloablative treatment, relapse deﬁned as a
time less than twelve months from diagnosis to recurrence
(early), and the presence of prognostic factors at relapse, as
deﬁned by IPI or secondary aaIPI (saaIPI) [33–35].
At present, the emphasis of recent clinical research in
HDT/ASCT is focused on three therapeutic aspects. The ﬁrst
consists in the evaluation of the potential beneﬁt of adding
rituximab to salvage therapy, followed by HDT/ASCT, in
relapsed rituximab na¨ ıve patients. Overall, the available data
in this setting of patients, although not completely con-
cordant, are in favour of the use of immunochemotherapy
(Table 4). In ﬁrst three studies reported in Table 4, no patient
[36] or only a minority of cases [37, 38]h a dr e c e i v e dr i t u x -
imab before enrollment, while, in the fourth, 25% of patients
weretreatedwithrituximabintheﬁrstlinetherapyorduring
salvage treatment or both at diagnosis and after relapse [39].
In the Kewalramani et al. study, the PFS rates of patients
who underwent HDT/ASCT after ICE in combination with
rituximab (RICE) were marginally improved compared to
thoseobservedinthehistoricalcontrolpatientswhoreceived
salvagetherapyalone[36].Thediﬀerencewasnotstatistically
signiﬁcant, but the study was not powered to detect minor
improvements in survival rates. However, in this study, the
addition of rituximab to ICE doubled the percentage of CRs.
Sieniawski et al., in their study reported improved OR rate,
freedom from second failure (FF2F), and OS in the patient
group treated with DHAP plus rituximab, compared to the
historical control group treated with the same chemotherapy
[37]. In both groups, patients in CR or PR after salvage
therapyreceivedHDStherapyfollowedbyBEAMwithASCT.
Improved FFS and PFS were documented also by Vellenga
et al. [38] in relapsed patients when rituximab was added to
DHAP-VIM-DHAPreinductiontherapy.Themodestimpact
of rituximab on OS was ampliﬁed when the analysis was
repeated adjusting for prognostic factors such as time elapse
since upfront treatment, saaIPI score, age, and WHO PS.
Furthermore, the addition of rituximab increased the group
of responders on reinduction therapy from 54% to 74% and
therefore the number of patients who might beneﬁt from
HDT/ASCT. In this study, as well, only patients in CR or
PR after salvage therapy were eligible for HDT/ASCT. In the
Mounier et al. study [39], after HDT/ASCT, the 5-year OS
was 63% (95 CI, 58–67%), and the 5-year DFS was 48%
(95CI,43–53%)fortheentirepopulation.Statisticalanalysis
indicated a signiﬁcant increase in DFS after ASCT compared
withdurationofCRI(median,51monthsversus11months;
P<. 001). This diﬀerence remained highly signiﬁcant in
patients with previous exposure to rituximab (median, 10
months versus not reached; P<0.01). The second aspect
regards the role of rituximab in salvage treatment of patients
previously treated with immunochemotherapy (Table 5). In
fact, at present, almost all patients with aggressive B-cell
NHL are initially treated with rituximab in association
with CHOP or CHOP-like regimens. In these patients, the
role of rituximab in further salvage treatment remains to beAdvances in Hematology 7
Table 4: Rituximab-based salvage therapy in rituximab-na¨ ıve relapsing/refractory DLBCLs.
Author Year n Pathological
phenotype
DLCL
(%) Therapy Conditioning
regimen
PFS/EFS
(%) P OS (%) P
Kewalramani [36] 2004 36
147 WHO 100 R-ICE
ICE
∗ 2y:54
2y:43 N.S. 2y:67
2y:56 N.S.
Sienawski [37] 2007 19
19 WHO 80 R-DHAP1
DHAP1 BEAM 2y:57
2y:18 0.0051 2y:77
2y:37 0.0051
Vallenga [38] 2008 113
112 WHO 80.5
78.6
R-DHAP-VIM-DHAP1
DHAP-VIM-DHAP1 BEAM 2y:52
2y:31 0.002 2y:59
2y:52 N.S.
Mounier [39] 2011 470 WHO 100 N.R. BEAM and
others# 5y:48 0.001∗∗ 5y:63 N.R.
1Plus radiotherapy at bulky disease.
∗The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy and the clinical trials active at the time of transplantation
(see [30]).
#See [39].
∗∗Each patient was assessed as his or her own control.
WHO: World Health Organization classiﬁcation of NHL; R: rituximab; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and
dexamethasone; VIM: etoposide, ifosfamide, and methotrexate; BEAM: carmustine, etoposide, cytarabine, and melphalan; N.R.: not reported; N.S.: not
signiﬁcant.
Table 5: Salvage therapy in relapsing/refractory DLBCLs previously exposed to rituximab.
Author Year Kind of
study n Pathological
phenotype
DLCL
(%) Therapy Conditioning
regimen
PFS/EFS
(%) P OS (%) P
Mart´ ın [40] 2008 Retrospective 94
69 WHO 100 R-ESHAP (prior R)
R-ESHAP (no prior R)
∗ 3y:17
3y: 57 0.008 3y:38
3y: 67 0.004
Fenske [41] 2009 Retrospective 818
176 WHO 100 R-CT (no prior R)
R-CT (prior R)
∗ 3y:50
3y:38 0.008 3y:57
3y:45 0.006
Gisselbrecht [42] 2010 Perspective 194
202 WHO 100 R-DHAP R-ICE BEAM 3y:42
3y:31 N.S. 2y:51
2y:47 N.S.
∗The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy, and the clinical trials active at the time of transplantation
(see [40, 41]).
WHO: World Health Organization classiﬁcation of NHL; R: rituximab; ESHAP: etoposide, methylprednisolone, cisplatin, and cytarabine; CT: multiple
variable regimes; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine,
and melphalan; N.S.: not signiﬁcant.
determined. In the GEL/TAMO report by Mart´ ın and col-
leagues [40], no signiﬁcant diﬀerences in response rates were
documentedinmultivariateanalysisbetweenpatientstreated
with R-ESHAP and previously exposed or not to rituximab.
However, patients who had received prior rituximab had a
signiﬁcantly worse PFS and OS than rituximab na¨ ıve pa-
tients. Furthermore, prior treatment with this monoclonal
antibody was also an independent adverse prognostic factor
for both PFS and OS. In the experience of Fenske et al. [41],
the administration of rituximab given with ﬁrst-line or
salvage therapy prior to HDT/ASCT was associated with
PFS and OS at 3 years superior to that observed when this
monoclonal antibody was not employed during the entire
therapeutic patient history. In the CORAL trial [42], the
response rates after salvage therapy were aﬀected by several
independentfactors.TheseincludesaaIPIscore,shortrelapse
time from diagnosis (<12 months), and prior rituximab
treatment. These same independent factors negatively inﬂu-
enced the 3-year EFS, PFS, and OS. However, patients relaps-
ingaftermorethan12monthsfromdiagnosisbeneﬁtedfrom
the introduction of rituximab into their salvage regimen and
showed 3-year EFS ranging from 40% to 50%. In conclusion,
at present, the optimal second-line regimen is not deﬁned,
andthebeneﬁtoftheinclusionofstandarddoseofrituximab
in salvage therapy for patients previously exposed to this
agent is also unclear although known risk factors might be
useful in choosing salvage therapeutic strategy. These factors
includesaaIPI,response(CRversusPRrefractory)toupfront
therapy disease status (early versus late relapse) at the time of
salvage therapy. The third aspect regards the development of
resistance to rituximab. One possibility in overcoming this
resistance consists in using high-dose (HD) of this antibody.
This therapeutic aspect was evaluated by Khouri et al. [43].
HD-rituximab (HD-R) was employed after mobilization
chemotherapy and again on day 1 and day 8 after HDT/
ASCT. In this study, the HDT consisted of standard BEAM.
Fifty-nine patients (88%) were exposed before to rituximab
during salvage chemotherapy. The median time from last
rituximab dose to study enrollment was 38 days. The re-
sults of this experience indicate that HD-R combined with
HDT/ASCT is feasible and eﬀective treatment in relapsed
patients previously treated with immunotherapy.
Anattempttodevelopmoreeﬀectivetherapeuticstrategy
for relapsed DLBCL patients consists in the combination of
radioimmunotherapy (RIT) with the standard chemother-
apy conditioning regimens. After Press et al. [44], ﬁrst estab-
lished the feasibility of high-dose RIT with ASCT, several
studies have used myeloablative RIT with promising results.8 Advances in Hematology
The RIT combined with high-dose chemotherapy was supe-
rior compared to historical data especially in the salvage of
patients with high IPI scores and residual PET-avid disease
[45]. To further increase the therapeutic potential of RIT,
Winter et al. [46] tested dose-escalated 90Y-ibriyumumab
tiuxetan combined with BEAM and ASCT. In this study, 30%
and 36% of the 44 treated patients had achieved less than a
PR to their most recent treatment or never had obtained CR.
Thus, respectively, 30% of cases would not have been eligible
for HDT/ASCT at most centers. The estimated 3-years PFS
and OS reported in this unfavorable series of patients were
43% and 60%, respectively. Careful dosimetry rather than
weight-based strategy for dose escalation was required to
avoid toxicity and under treatment.
Finally, one relevant prognostic factor associated with
DLBCL consists of the cell origin of malignant cells [47–
51]. In fact, the gene expression proﬁle (GEP) resembling
that of germinal center B cells (GCB) is predictive of better
patient outcome than a proﬁle resembling that of activated B
cells (ABC). Cell-of-origin (COO) algorithms [52, 53]c a n
also translate GEP data into practical applications. In the
prerituximab era, studies using conventional dose therapy
or HDT/ASCT concluded in favour of predictive prognostic
valueofCOO[48,51].Incontrast,theclinicalsigniﬁcanceof
DLBCL subtyping, as deﬁned by COO, is more controversial
in patients treated at diagnosis with immunochemotherapy
[53–56]. At relapse, few data regarding the clinical impact of
COO-subsets are available. Recently a subanalysis of Coral
trial [57] has indicated that COO retains its prognostic value
in relapse/refractory DLBCL patients. In addition, a better
response to R-DHAP was documented in GCB-like DLBCL
cases. In contrast with these ﬁndings, in the study by Gu
et al. [58], COO failed to predict survival in DLBCL patients,
either withchemosensitive or chemoresistant disease, treated
with HDT/ASCT. Further studies are needed to clarify the
predictive value of DLBCL subtyping in the setting of
patients with refractory/relapsing disease.
In conclusion, the beneﬁt of HDT/ASCT for refractory
or relapsed DLBCL is restricted to patients with immun-
ochemosensitive disease. In fact, the response to second-
line treatment seems to predict patient outcome after HDT/
ASCT.
Diﬀerent therapeutic approaches are required to salvage
patients with disease resistant to rituximab and chemother-
apy. New agents such anti-CD20 antibodies therapeutically
more active than rituximab, radiolabeled-antibodies, his-
tone deacetylase inhibitors, various molecules which target
mTOR, inhibitor of protein Kinase Cβ, and other types of
target therapy might be eﬀective in controlling refractory-
relapsing DLBLC.
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